The ability of Aneurinibacillus migulanus (Bacillus brevis) to produce the antibiotic gramicidin S is correlated with phenotype variation.
Phenotype instability of bacterial strains can cause significant problems in biotechnological applications, since industrially useful properties may be lost. Here we report such degenerative dissociation for Aneurinibacillus migulanus (formerly known as Bacillus brevis) an established producer of the antimicrobial peptide gramicidin S (GS). Phenotypic variations within and between various strains maintained in different culture collections are demonstrated. The type strain, ATCC 9999, consists of six colony morphology variants, R, RC, RP, RT, SC, and SP, which were isolated and characterized as pure cultures. Correlations between colony morphology, growth, GS production, spore formation, and resistance to their own antimicrobial peptide were established in this study. We found the original R form to be the best producer, followed by RC, RP, and RT, while SC and SP yielded no GS at all. Currently available ATCC 9999(T) contains only 2% of the original R producer and is dominated by the newly described phenotypes RC and RP. No original R form is detected in the nominally equivalent strain DSM 2895(T) (=ATCC 9999(T)), which grows only as SC and SP phenotypes and has thus completely lost its value as a peptide producer. Two other strains from the same collection, DSM 5668 and DSM 5759, contain the unproductive SC variant and the GS-producing RC form, respectively. We describe the growth and maintenance conditions that stabilize certain colony phenotypes and reduce the degree of degenerative dissociation, thus providing a recommendation for how to revert the nonproducing smooth phenotypes to the valuable GS-producing rough ones.
Berditsch
Marina
M
University of Karlsruhe (TH), Institute of Organic Chemistry, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany. anne.ulrich@ibg.fzk.de.
Afonin
Sergii
S
Ulrich
Anne S
AS
D000900:Anti-Bacterial Agents / Q000096:biosynthesis* / Q000494:pharmacology; D001407:Bacillus / Q000145:classification* / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D001709:Biotechnology / Q000379:methods; D003470:Culture Media; D024881:Drug Resistance, Bacterial; D006096:Gramicidin / Q000096:biosynthesis* / Q000494:pharmacology; D010641:Phenotype; D013171:Spores, Bacterial / Q000502:physiology
D000900:Anti-Bacterial Agents; D003470:Culture Media; D006096:Gramicidin